Bullish on Inventiva (IVA) as a late-stage Phase 3 MASH drug developer with an oral candidate that could be the second approved MASH drug.
IVA — LONG The author is bullish on Inventiva, which is in the final stages of Phase 3 trials for its MASH drug lanifibranor. The drug is taken orally, unlike Madrigal's, and the author claims results are impressive, positioning it to become the second approved drug in the large MASH market. The author notes the company is under the radar, similar to Abivax previously, and states 'I'm in!'
They are in the final stages of Phase 3 trials for their MASH drug: lanifibranor.
This Reddit post, published January 13, 2026, features u/Beautiful-Cod-3414 discussing IVA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Beautiful-Cod-3414 · Tickers: IVA